The FDA approval of PD-1 inhibitors (Pembrolizumab) have diversified the clinical activity toward a wide variety of solid tumors including lung cancer, renal cell cancer, and ovarian cancer [20]. The gene discussed is PDCD1; the disease is renal cell adenocarcinoma.